Esperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference
March 28 2017 - 4:30PM
Fireside Chat on Tuesday, April 4, 2017 at 1:40
p.m. Eastern Time
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management
company focused on developing and commercializing convenient,
complementary, cost-effective and consistent once-daily oral
therapies for the treatment of patients with elevated low density
lipoprotein cholesterol (LDL-C), today announced that chief medical
officer, Mary P. McGowan, M.D., and senior vice president of
product planning, Marianne Andreach, will participate in an
analyst-led fireside chat with investors at the 16th Annual Needham
Healthcare Conference in New York City on Tuesday, April 4, 2017 at
1:40 p.m. Eastern Time.
Bempedoic Acid
With a targeted mechanism of action, bempedoic acid is a
first-in-class, orally available, once-daily ACL inhibitor that
reduces cholesterol biosynthesis and lowers elevated levels of
LDL-C by up-regulating the LDL receptor, but may potentially reduce
the occurrence of muscle-related side effects. Completed Phase 1
and 2 studies in more than 800 patients treated with bempedoic acid
have produced clinically relevant LDL-C lowering results of up to
30 percent as monotherapy, approximately 50 percent in combination
with ezetimibe, and an incremental 20+ percent when added to stable
statin therapy.
Esperion's Commitment to Patients with
Hypercholesterolemia
In the United States, 78 million people, or more than 20 percent
of the population, have elevated LDL-C; an additional 73 million
people in Europe and 30 million people in Japan also live with
elevated LDL-C. Esperion's mission as the lipid management company
is to provide patients and physicians with convenient,
complementary, cost-effective and consistent once-daily oral
therapies to significantly reduce elevated levels of LDL-C in
patients inadequately treated with current lipid-modifying
therapies. It is estimated that 40 million patients in the
U.S. are taking statins with approximately 5-20 percent of
these patients only able to tolerate less than the lowest approved
daily starting dose of their statin and considered statin
intolerant. Esperion-discovered and developed, bempedoic acid is a
targeted LDL-C lowering therapy in Phase 3 development. The Company
has two Phase 3 products in development: 1) bempedoic acid
(monotherapy) an oral, once-daily pill, and 2) an, oral, once-daily
fixed dose combination pill of bempedoic acid and ezetimibe
(BA+EZ).
The Lipid Management Company
Esperion Therapeutics, Inc. is the lipid management company
passionately committed to developing and commercializing
convenient, complementary, cost-effective and
consistent once-daily oral therapies for the treatment of
patients with elevated LDL-C. Through scientific and clinical
excellence, and a deep understanding of cholesterol biology, the
experienced lipid management team at Esperion is committed to
developing new LDL-C lowering therapies that will make a
substantial impact on reducing global CVD; the leading cause of
death around the world. Bempedoic acid, the Company's lead product
candidate, is a targeted therapy that has been shown to
significantly reduce elevated LDL-C levels in patients with
hypercholesterolemia, including patients inadequately treated with
current lipid-modifying therapies. For more information, please
visit www.esperion.com and follow us on Twitter
at https://twitter.com/EsperionInc.
Media Contact:
Elliot Fox
W2O Group
212.257.6724
efox@w2ogroup.com
Investor Contact:
Mindy Lowe
Esperion Therapeutics, Inc.
734.887.3903
mlowe@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Sep 2023 to Sep 2024